Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
Leah Andrews, M. Elizabeth Halloran, Lars van der Laan, Yunda Huang et autres
6 citationsJAMA Network Open
Amina Z. Haggag
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
11Publications signalées
185Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesDiabetes Treatment and ManagementLong-Term Effects of COVID-19vaccines and immunoinformatics approaches
Publications récentes
A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics, safety, and tolerability of PERT-IJS following a single dose of 420 mg intravenous infusion compared to the EU- and US-marketed drug product (pertuzumab; PERT) in healthy male volunteers.
Subramanian Loganathan, Jelle Klein, Amina Z. Haggag, Andrew Shaw et autres
1 citationJournal of Clinical Oncology
Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist
Amina Z. Haggag, Jianfeng Xu, Laurie Butcher, Sandra Pagnussat et autres
19 citationsDiabetes Obesity and Metabolism
Author response for "Non‐clinical and first‐in‐human characterization of ECC5004 / AZD5004 , a novel once‐daily, oral small‐molecule GLP ‐1 receptor agonist"
Amina Z. Haggag, Jianfeng Xu, Laurie Butcher, Sandra Pagnussat et autres
0 citations
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
Neeta B. Amin, Robert Frederich, Nikolaos Tsamandouras, Amina Z. Haggag et autres
28 citationsDiabetes Obesity and Metabolism
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals
Leigh H. Fisher, Jia Jin Kee, Albert Liu, Claudia Espinosa et autres
6 citationsJAMA Network Open
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector P. Rodríguez, Xia Xu et autres
21 citationsClinical Infectious Diseases
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers
Ahmed Nader, Elizabeth Alexander, Dimitra Brintziki, Amina Z. Haggag et autres
5 citationsClinical Pharmacokinetics
Risk of COVID-19 after natural infection or vaccination
Anne-Marie Rick, Matthew B. Laurens, Ying Huang, Chenchen Yu et autres
15 citationsEBioMedicine
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
Deborah Theodore, Angela R Branche, Lily Zhang, Daniel S. Graciaa et autres
23 citationsJAMA Network Open
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine
Timo Vesikari, Adam Finn, Pierre Van Damme, Isabel Leroux‐Roels et autres
61 citationsJAMA Network Open
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.